Welcome to the BioLogicTube

Dr. Jesper Eugen-Olsen talks on suPAR and Chronic inflammation

Tue, 16 Jul 2024 10:41:27 GMT

Dr Eugen-Olsen talks on chronic inflammation and how it is linked to the development of disease. The lecture is from the Longevity and Biohacking Conference in Andorra, July 2024 and is named "Cracking the longevity code: Measuring and mastering chronic inflammation"

Prof. Peter Rossing on diabetes complications

Wed, 03 Jul 2019 12:53:40 GMT

Patients with type 1 diabetes are prone to develop complications such as kidney or heart disease. Professor Peter Rossing and his group are working on biomarkers that may predict which patients are in risk of developing these complications. Peter talks about their latest work on the risk biomarker suPAR and its predictive abilities. Their study "Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes" were published in Diabetes Care in 2019 (https://care.diabetesjournals.org/content/42/6/1112.long)

Interview with first author Viktor Curovic on his work on suPAR in diabetes...

Tue, 25 Jun 2019 14:28:33 GMT

interview on the following publication:

Diabetes Care. 2019 Jun;42(6):1112-1119. doi: 10.2337/dc18-1427. Epub 2019 Mar 18.
Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes.
Rotbain Curovic V1, Theilade S2, Winther SA2, Tofte N2, Eugen-Olsen J3, Persson F2, Hansen TW2, Jeppesen J4,5, Rossing P2,5.
Author information
Abstract
OBJECTIVE:
RESEARCH DESIGN AND METHODS:
RESULTS:
CONCLUSIONS:

Soluble urokinase plasminogen activator receptor (suPAR) is an important inflammatory biomarker implicated in endothelial and podocyte dysfunction. However, suPAR's predictive qualities for complications in type 1 diabetes have yet to be determined. We investigated the prognostic value of suPAR for the development of cardiovascular events, decline in renal function, and mortality in patients with type 1 diabetes.

We included 667 patients with type 1 diabetes with various degrees of albuminuria in a prospective study. End points were cardiovascular events (cardiovascular death, nonfatal acute myocardial infarction, nonfatal stroke, or coronary or peripheral arterial interventions), estimated glomerular filtration rate (eGFR) decline ≥30%, progression from lower to higher albuminuric state, development of end-stage renal disease (ESRD), and mortality. Follow-up was 5.2-6.2 years. Results were adjusted for known risk factors. Hazard ratios (HRs) are presented per doubling of suPAR with 95% CI. Relative integrated discrimination improvement (rIDI) was calculated.

Quantification of suPAR was available in all participants; median (interquartile range) was 3.4 ng/mL (2.7-4.5). The adjusted HR (95% CI) for cardiovascular events (n = 94), progression in albuminuria (n = 36), eGFR decline (n = 93), ESRD (n = 23), and mortality (n = 58) were 3.13 (1.96-5.45, P < 0.001), 1.27 (0.51-3.19, P = 0.61), 2.93 (1.68-5.11, P < 0.001), 2.82 (0.73-11.9, P = 0.13), and 4.13 (1.96-8.69, P < 0.001), respectively. rIDI was significant for cardiovascular events (22.6%, P < 0.001), eGFR decline (14.4%, P < 0.001), and mortality (23.9%, P < 0.001).

In patients with type 1 diabetes and a broad range of albuminuria, a higher level of suPAR is a significant and independent risk factor for cardiovascular events, decline in eGFR ≥30%, and mortality. In addition, suPAR contributes significantly to discrimination for the end points.

suPAR - From basic research to routine clinical use - Danish speak

Sun, 10 Apr 2016 20:54:55 GMT

suPAR is today a routine marker used for accessing disease severity and prognosis in the Emergency Department. The movie is produced by Copenhagen University Hodpital Hvidovre. Photo and edit Peter Bak

suPARnostic Quick Triage Test Instruction Video

Wed, 17 Jun 2015 09:02:43 GMT

Instruction video for the quantitation of suPAR in plasma using the Quick Triage test. The test is based on the lateral flow principle and quantifies the patient plasma suPAR value (The new updated quantitative Quick triage test). The time from plasma sample to final result is about 24 minutes. The suPARnostic Quick Triage Test is produced by ViroGates, Denmark. More information on suPAR measuring products can be found at www.suPARnostic.com

suPAR Acute Care Triage marker at ESOF, Copenhagen 2014

Tue, 15 Jul 2014 14:57:15 GMT

In June 2014, The European Science Open Festival was held in Copenhagen, Denmark. Jesper Eugen-Olsen and Jakob Knudsen presented the suPARnostic® Quick Triage system for quick determination of the plasma suPAR level. The product is developed by the Danish company ViroGates A/S. For more info, please visit www.ViroGates.com

Dr. Rafal Wlazel talks on suPAR and prediction of AMI in pPCI patients

Fri, 13 Jun 2014 11:41:26 GMT

The 5th international suPAR symposium was held in Amsterdam 8 and 9th of May 2014. The symposium was entitled suPAR and its clinical use and focused on suPAR as a triage marker in the emergency room. The symposium was hosted by professor Marcus Schultz from the Amsterdam Medical Center. Dr. Wlazel's presentation was one of 25 lectures gicen over the 2-day Internationl suPAR symposium

The 4'th International suPAR symposium overview

Tue, 21 May 2013 18:55:50 GMT

Almost 100 researchers met to present new data and discuss the potential of the suPAR biomarker in triage in the emergency room and ICU setting.

The 4th International suPAR symposium was held in late February in 2013 in Aachen, Germany.

This years suPAR symposium was entitled ” New Horizons for suPAR: Risk Stratification, Organ Dysfunction and Relevance for Specific Diseases”.

Almost 100 researchers from all over the world met to discuss the potential use of the prognostic biomarker suPAR.

The symposium was hosted by Professor Frank Tacke and Dr Alexander Koch from Aachen University Hospital

The talks started with insights into suPAR biology and pathology with ”state of the art lecture” given by professor Jochen Reiser from Chicago on the causative effect of suPAR in kidney diseases. This was followed by an overview on suPAR in Kidney diseases, liver diseases and finally in pulmonary diseases.

The overviews were followed by presentations on exciting new data on suPAR in liver cirrhosis – where does suPAR come from, how is it regulated, what is its prognostic relevance?

Following this, new data on the role of suPAR in low-grade inflammation, Atherosclerosis and Life Style Diseases were presented and discussed and approximately half of the attendees had their blood drawn for suPAR measurement

Hereafter chief Physician Jyrki Tenhunen gave an overview on the large amount of data published within the last year with emphesis on sepsis

Finally, on day 1, new data on suPAR and its prognostic value in Inflammatory and Infectious Diseases and Sepsis were presented and the Usefulness of suPAR in Risk Stratification of Patients with sepsis Admitted to the Emergency Department were discussed

As the day turned into night, the researchers met to socialize and exchange ideas at the suPARTY.

On day 2, after some black coffee, the researchers presented data and discussed how biomarkers may aid in clinical decision making – in particular in sepsis, Cardiology, Kidney failure, liver failure and finally in cancer.The last session gave insight into the use of suPAR as a marker of triaging in the emergency department. And Katia Donadello closed the symposium with a presentation on the potential use of suPAR in the intensive care unit.